BR112022010733A2 - Métodos para tratar dor - Google Patents

Métodos para tratar dor

Info

Publication number
BR112022010733A2
BR112022010733A2 BR112022010733A BR112022010733A BR112022010733A2 BR 112022010733 A2 BR112022010733 A2 BR 112022010733A2 BR 112022010733 A BR112022010733 A BR 112022010733A BR 112022010733 A BR112022010733 A BR 112022010733A BR 112022010733 A2 BR112022010733 A2 BR 112022010733A2
Authority
BR
Brazil
Prior art keywords
methods
treat pain
compound
present
directed
Prior art date
Application number
BR112022010733A
Other languages
English (en)
Portuguese (pt)
Inventor
Philip Johnson James Jr
N Beatch Gregory
Original Assignee
Xenon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xenon Pharmaceuticals Inc filed Critical Xenon Pharmaceuticals Inc
Publication of BR112022010733A2 publication Critical patent/BR112022010733A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
BR112022010733A 2019-12-06 2020-12-04 Métodos para tratar dor BR112022010733A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962945093P 2019-12-06 2019-12-06
US201962948010P 2019-12-13 2019-12-13
PCT/US2020/063471 WO2021113757A1 (en) 2019-12-06 2020-12-04 Use of a kv7 potassium channel opener for treating pain

Publications (1)

Publication Number Publication Date
BR112022010733A2 true BR112022010733A2 (pt) 2022-08-23

Family

ID=73856375

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022010733A BR112022010733A2 (pt) 2019-12-06 2020-12-04 Métodos para tratar dor

Country Status (14)

Country Link
EP (1) EP4069211A1 (ja)
JP (1) JP2023504166A (ja)
KR (1) KR20220113411A (ja)
CN (1) CN114786658A (ja)
AU (1) AU2020397173A1 (ja)
BR (1) BR112022010733A2 (ja)
CA (1) CA3159436A1 (ja)
CL (1) CL2022001477A1 (ja)
CR (1) CR20220318A (ja)
IL (1) IL293504A (ja)
MX (1) MX2022006877A (ja)
PE (1) PE20221169A1 (ja)
TW (1) TW202133847A (ja)
WO (1) WO2021113757A1 (ja)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113698345B (zh) * 2021-10-27 2022-02-01 上海挚盟医药科技有限公司 作为钾通道调节剂的化合物及其制备和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8993593B2 (en) * 2006-08-23 2015-03-31 Valeant Pharmaceuticals International N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
PL2061465T3 (pl) 2006-08-23 2014-03-31 Valeant Pharmaceuticals Int Pochodne 4-(N-azacykloalkilo) anilidów jako modulatory kanałów potasowych
WO2013067591A1 (en) * 2011-11-10 2013-05-16 Relevare Australia Pty Ltd Topical formulations for pain management
US9248122B2 (en) * 2012-11-28 2016-02-02 Grünenthal GmbH Heteroquinoline-3-carboxamides as KCNQ2/3 modulators
DK3790548T3 (da) * 2018-05-11 2023-11-13 Xenon Pharmaceuticals Inc Fremgangsmåder til forbedring af biotilgængeligheden og eksponeringen af en åbner af spændingsstyret kaliumkanal

Also Published As

Publication number Publication date
CA3159436A1 (en) 2021-06-10
IL293504A (en) 2022-08-01
CL2022001477A1 (es) 2023-04-28
PE20221169A1 (es) 2022-07-25
MX2022006877A (es) 2022-07-11
CN114786658A (zh) 2022-07-22
KR20220113411A (ko) 2022-08-12
CR20220318A (es) 2022-10-07
WO2021113757A1 (en) 2021-06-10
TW202133847A (zh) 2021-09-16
JP2023504166A (ja) 2023-02-01
AU2020397173A1 (en) 2022-06-23
EP4069211A1 (en) 2022-10-12

Similar Documents

Publication Publication Date Title
BR112019005930A2 (pt) combinações compreendendo um inibidor de ssao/vap-1 e um inibidor de sglt2, e usos das mesmas
BR112016014481A2 (pt) tratamento de câncer utilizando combinações de inibidores de erk e raf
BR112015010477A2 (pt) combinação farmacêutica que compreende um inibidor b-raf e um inibidor de histona desacetilase e o uso dos mesmos no tratamento de doenças proliferativas
EA201591610A1 (ru) Ингибиторы кинуренинового пути
BR112017017448A2 (pt) métodos e composições para o tratamento de doença do olho ressecado e outros distúrbios do olho
BR112015029918A2 (pt) uso de alta dose de pridopidina para tratar a doença de huntington
EA201590166A8 (ru) Комбинированная терапия для лечения рассеянного склероза
EA201490163A1 (ru) Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
MX2017006938A (es) Terapia de combinacion para el tratamiento de cancer.
BR112016000335A8 (pt) método de tratamento da rosácea papulopustular, de tratamento de lesões inflamatórias da rosácea papulopustular e uso de uma composição farmacêutica
PH12020551898A1 (en) Methods for enhancing the bioavailability and exposure of a voltage-gated potassium channel opener
BR112021017314A2 (pt) Uso de extrato de elaeocarpus sylvestris
BR112022016360A2 (pt) Uso de inibidores de sglt-2 para a prevenção e/ou tratamento de doenças cardíacas em felinos
BR112022008580A2 (pt) Métodos para tratar transtornos depressivos
BR112021025764A2 (pt) Derivado de pirimidina que inibe o crescimento de células cancerígenas e uso medicinal do mesmo
MX2018008903A (es) COMPOSICIONES Y METODOS DE USO DE ß-HIDROXI-ß-METILBUTIRATO (HMB) PARA MODULAR AUTOFAGIA Y LIPOFAGIA.
BR112023023030A2 (pt) Composições e métodos para o tratamento de depressão
BR112015021265A2 (pt) métodos de aperfeiçoamento de uso para secretoglobinas humanas recombinantes
BR112022010733A2 (pt) Métodos para tratar dor
BR112021009616A8 (pt) Composição cicatrizante que compreende água eletrolisada e máscara de aplicação cutânea
BR112015023806A2 (pt) Novos regimes de dosagem de celgosivir para o tratamento de dengue
CO2023014650A2 (es) Dosificación y administración de l-asparaginasa recombinante
EA202091653A1 (ru) Миноциклин для лечения воспалительных заболеваний кожи
CL2021003312A1 (es) Composición que comprende pridopidina y un análogo de la misma para el tratamiento de la enfermedad de huntington y síntomas de la misma.
BR112014001503A2 (pt) composições farmacêuticas compreendendo 4-bromo-n-(imidazolidin-2-ilideno)-1h-benzimidazol-5-amina para o tratamento de doenças de pele